Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Growth Rate of the Self-Administered Parenteral Market?
In recent times, the market size of self-administered parenteral has significantly expanded. The market is forecast to increase from $24.57 billion in 2024 to $26.04 billion in 2025, with a compound annual growth rate (CAGR) of 6.0%. The surge in growth witnessed in the historical period is due to factors such as an increase in chronic diseases, an aging population, governmental initiatives, patient education and support programs, and a rise in bone disorder cases.
What Growth Rate Is Forecasted for the Self-Administered Parenteral Market by 2029?
A consistent increase in the size of the self-administered parenteral market is predicted for the upcoming years, and it is projected to reach $31.18 billion in 2029, with a compound annual growth rate (CAGR) of 4.6%. Factors contributing to the growth during the forecast period include the rising preference of patients for home healthcare, advancements in telemedicine and remote patient monitoring, as well as initiatives aimed at patient education and support, and the expansion of personalized medicine. The forecast period will see trends like digital health solutions integration, customized drug delivery systems, the rise of targeted therapies, and breakthroughs in biologics.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13927&type=smp
Which Key Companies Are Shaping the Future of the Self-Administered Parenteral Market?
Major companies operating in the self-administered parenteral market report are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., AstraZeneca PLC, Roche Holding AG, Eli Lilly and Company, Novo Nordisk A/S, Becton, Dickinson and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Terumo Corporation, Catalent Inc., Dexcom Inc., West Pharmaceutical Services Inc., Gerresheimer AG, Biocon Limited, Insulet Corporation, Halozyme Therapeutics Inc., Ypsomed AG, Antares Pharma Inc., SHL Medical AG, Owen Mumford Ltd., Novartis AG, Kaleo Inc., Haselmeier AG, Bespak (A Consort Medical Company), Senseonics Holdings Inc., ScPharmaceuticals Inc., Fresenius Kabi AG
Which Factors Are Driving Demand in the Self-Administered Parenteral Industry?
The upward trend in chronic disease incidents is projected to fuel the expansion of the self-administered parenteral market. Chronic diseases are enduring health issues that usually gradually develop and frequently necessitate continuous management and treatment. Self-administered parenteral products assist in the management of chronic diseases by enabling independent treatment, which can significantly enhance adherence compared to oral drugs. For example, the National Institutes of Health, a government agency based in the USA, projected in January 2023 that the number of individuals aged 50 or above with at least one chronic ailment is anticipated to rise by 99.5% from 71.522 million in 2020 to 142.66 million by 2050. Consequently, the escalating prevalence of chronic diseases is fostering the growth of the self-administered parenteral market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=13927&type=smp
How Is the Self-Administered Parenteral Market Segmented by Several Divisions?
The self-administered parenteral market covered in this report is segmented –
1) By Product: Pre-Filled Syringes, Autoinjectors, Pen Injectors, Other Products
2) By Usage: Disposable, Reusable
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Home Healthcare Providers, Specialty Clinics, Other Distribution Channels
4) By Application: Cardiovascular Diseases, Diabetes, Osteoporosis, Pain Management, Hormone Replacement, Other Applications
Subsegments:
1) By Pre-Filled Syringes: Glass Pre-Filled Syringes, Plastic Pre-Filled Syringes
2) By Autoinjectors: Disposable Autoinjectors, Reusable Autoinjectors
3) By Pen Injectors: Insulin Pen Injectors, Growth Hormone Pen Injectors, Other Pen Injectors
4) By Other Products: Infusion Pumps, Needle-Free Injectors, Combination Devices
What are the Emerging Market Trends Driving the Growth of the Self-Administered Parenteral Industry?
Leading brands in the self-administered parenteral market are concentrating on the creation of cutting-edge products like the UDENYCA autoinjector, to give more options and power to the patients, consequently making the treatment more reachable. Defined as a medical tool, an autoinjector is crafted to administer a single dosage of a specific medication and is devised with a user-friendly layout that triggers prompt and dependable administration upon skin contact. For example, the US-based biotechnology firm, Coherus BioSciences Inc., unveiled the UDENYCA autoinjector, a self-administered parenteral drug in the US in May 2023. The UDENYCA Autoinjector is a prefilled autoinjector containing a single dose, offering an alternative method of administering pegfilgrastim to patients. It is designed with simplicity in mind, activating upon skin contact to ensure reliable and immediate delivery of a full pegfilgrastim dose. The device also provides numerous features catering to user convenience, including speedy dosing, effortless design, dual coverage, suitability for both home and office usage, and reduced risk of febrile neutropenia.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/self-administered-parenteral-global-market-report
Which Regions Are Driving Growth in the Self-Administered Parenteral Market?
North America was the largest region in the self-administered parenteral market in 2024. The regions covered in the self-administered parenteral market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13927
This Report Delivers Insight On:
1. How big is the self-administered parenteral market, and how is it changing globally?
2. Who are the major companies in the self-administered parenteral market, and how are they performing?
3. What are the key opportunities and risks in the self-administered parenteral market right now?
4. Which products or customer segments are growing the most in the self-administered parenteral market?
5. What factors are helping or slowing down the growth of the self-administered parenteral market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model